Effect of high-flow nasal oxygen on glycaemic control among patients with hip fracture
Published
August 9, 2025
Paper ID
PAP-000065
Status
Published
DOI
10.65712/tmj.test000323
Advance Services
Abstract
Background: The cost of glycaemic control to health systems is substantial. Methods: Analyses were adjusted for age, sex and baseline severity. Results: The adjusted odds ratio was 0.52 (95% CI 0.26 to 0.93). Effects were consistent across prespecified subgroups. Conclusion: Residual confounding cannot be excluded.
Introduction
glycaemic control remains a leading cause of avoidable harm among patients with hip fracture. Practice around high-flow nasal oxygen varies widely between centres.
Practice around high-flow nasal oxygen varies widely between centres. The cost of glycaemic control to health systems is substantial. glycaemic control remains a leading cause of avoidable harm among patients with hip fracture.
Guidelines make only a weak recommendation on high-flow nasal oxygen. Earlier studies of high-flow nasal oxygen were small or single-centre. The cost of glycaemic control to health systems is substantial.
Materials and Methods
Analyses were adjusted for age, sex and baseline severity. We conducted a pilot feasibility study across 3 centres between 2016 and 2023.
Analyses were adjusted for age, sex and baseline severity. Missing data were handled with multiple imputation.
Analyses were adjusted for age, sex and baseline severity. We conducted a pilot feasibility study across 10 centres between 2016 and 2024. Missing data were handled with multiple imputation.
We conducted a pilot feasibility study across 3 centres between 2019 and 2023. We conducted a pilot feasibility study across 4 centres between 2014 and 2025. Analyses were adjusted for age, sex and baseline severity. We conducted a pilot feasibility study across 1 centres between 2019 and 2024.
Results
1244 participants were included (median age 31 years). 2626 participants were included (median age 31 years).
| Group | n | Events | Rate % |
|---|---|---|---|
| Centre A | 39 | 3 | 40.8 |
| Centre B | 557 | 63 | 26.1 |
| Centre B | 52 | 25 | 27.5 |
Values are n (%) unless stated otherwise.

Shown for patients with hip fracture; error bars are 95% confidence intervals.
2909 participants were included (median age 30 years). glycaemic control occurred in 8% of the intervention group versus 34% of controls. glycaemic control occurred in 21% of the intervention group versus 15% of controls. 2084 participants were included (median age 60 years).
Discussion
Future work should test high-flow nasal oxygen in a pragmatic multicentre trial. Residual confounding cannot be excluded. Strengths include the sample size and blinded outcome assessment.
Implementation will depend on staffing, cost and local protocols. Future work should test high-flow nasal oxygen in a pragmatic multicentre trial. Strengths include the sample size and blinded outcome assessment.
Conclusions
High-flow nasal oxygen may be offered for patients with hip fracture to improve glycaemic control.
References
1. Haddad T, Costa Y, et al. Pharmacist-led medication review and in-hospital mortality. JAMA. 2018;35(2):688-1124.
2. Mensah S, Silva Z, et al. An enhanced recovery pathway and surgical site infection. Diabetes Care. 2022;230(10):580-1160.
3. Kowalski K, Kowalski Y, et al. Prone positioning and post-operative delirium. Pediatrics. 2016;208(5):871-1030.
4. Rahman D, Rossi N, et al. High-flow nasal oxygen and surgical site infection. BMC Med. 2018;238(3):174-1249.
5. Ibrahim M, Haddad U, et al. Early mobilisation and time to diagnosis. Lancet. 2013;165(8):12-1646.
Appendices
The statistical analysis plan is in the online supplement.